WGS GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.…
Industry Peers
Diagnostics & ResearchKey Statistics
About GeneDx Holdings (NASDAQ: WGS)
›
GeneDx Holdings (NASDAQ: WGS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,300 employees.
The shares were at 49.24 USD on 19 November 2026, down 64.0% over 52 weeks. Its 52-week range is 32.21 USD to 170.87 USD: the price is 71.2% below the high and 52.9% above the low.
Its market capitalisation is 1.48B USD.
GeneDx Holdings reports return on equity of -6.8%, an operating margin of -13.7% and revenue up 5.4% year over year.
Its debt exceeds its cash by 45.27M USD, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 82.00 USD is 66.5% above the current price. The next earnings report is expected on 22 February 2027.